ROCKVILLE, Md. – The landscape of precision medicine is undergoing a seismic shift. For decades, the field of pharmacogenomics—the study of how genes affect a person’s response to drugs—has been dominated by the examination of single gene-drug pairs. However, a new generation of scientists is moving beyond this traditional model, aiming to bridge the gap between genetic code and real-world clinical outcomes.
On Friday, October 23, 2026, the American Society of Human Genetics (ASHG) announced a pioneering, trainee-led session designed to redefine the boundaries of drug response research. By integrating multiomic data, functional genomics, and diverse population datasets, researchers are moving toward a more holistic, inclusive, and clinically actionable understanding of why medications work for some, but fail—or cause adverse reactions—in others.
The Evolution of Pharmacogenomics: Moving Beyond the "Single-Gene" Paradigm
Historically, pharmacogenomics focused on identifying specific variants, such as those in the CYP450 family of enzymes, that dictate how the body metabolizes certain drugs. While this has been instrumental in clinical practice, it provides only a partial picture.
"We are entering an era where individual gene-drug pairs are no longer sufficient to capture the complexity of human biology," noted an ASHG representative. "The next phase of pharmacogenomics requires us to look at the ‘interactome’—the complex interplay of genomics, proteomics, metabolomics, and the environment."
The upcoming session will showcase how researchers are shifting their focus to the intersection of genomic variation and broad drug responses. Unlike many variants associated with complex diseases, which often carry small, incremental effects, pharmacogenomic variants frequently exert a substantial influence on treatment efficacy and safety. These "actionable" variants are the primary targets of the new multiomic approach.
Chronology: From Candidate Genes to Systems Biology
The trajectory of this field has been rapid and transformative. Understanding the timeline of these advancements highlights why the current shift toward multiomics is so significant:
- 1950s–1990s: The Discovery Phase. Early researchers identified the first "pharmacogenetic" traits, such as succinylcholine sensitivity. These studies were limited to rare, Mendelian-style genetic variations.
- 2000s–2015: The GWAS Era. The completion of the Human Genome Project ushered in Genome-Wide Association Studies (GWAS). This period expanded the catalog of drug-response variants significantly, though many findings remained restricted to populations of European ancestry.
- 2016–2024: The Biobank Explosion. Large-scale initiatives like the UK Biobank and the All of Us Research Program allowed for the connection of genotype data to electronic health records (EHRs) at an unprecedented scale.
- 2025–Present: The Multiomic and Integrative Era. Researchers are now moving beyond simple association to functional validation. By utilizing cellular models and CRISPR-based drug perturbations, scientists are now testing why a specific variant leads to a drug-response failure, rather than just noting the association.
Integrating Diverse Datasets: The Power and the Pitfall
The integration of electronic health records (EHRs) and large-scale biobanks has become the cornerstone of modern pharmacogenomics. However, as the ASHG session will emphasize, these tools are a double-edged sword.
The Benefits of Scale
Large databases provide the statistical power necessary to detect rare variants that influence drug response. By leveraging millions of patient records, researchers can identify patterns of adverse drug reactions (ADRs) that would be impossible to detect in small clinical trials.
The Challenge of Representation
A critical issue that will be front-and-center in the discussion is the "diversity gap." Much of the current pharmacogenomic data is skewed toward populations of European descent. This creates a dangerous disparity: clinical algorithms based on these data may be inaccurate—or even harmful—when applied to individuals of African, Asian, or Hispanic ancestry.
The session will explore how to rectify this by prioritizing research into historically understudied populations. Speakers will argue that true precision medicine cannot exist if the "precision" only applies to a subset of the global population.
Innovative Methodologies: The New Toolkit
How are scientists actually capturing this "complete picture"? The session will highlight several emerging techniques that are currently reshaping the laboratory:
Omics Profiling and Cellular Perturbation
By exposing cellular models (such as organoids or iPSCs) to specific drugs and measuring the resulting transcriptomic and proteomic changes, scientists can map the biological pathways affected by a drug. This allows for a "systems" view of drug response, where researchers can observe how a drug interacts with thousands of proteins simultaneously.
Functional Genomic Assays
Rather than waiting for patient outcomes, researchers are using functional assays to predict responses. These assays allow scientists to simulate drug-gene interactions in a controlled environment, providing a mechanical explanation for observed clinical phenotypes.
Environmental and Social Determinants
Biology does not exist in a vacuum. The session will highlight how researchers are now incorporating social determinants of health (SDOH)—such as diet, socioeconomic status, and environmental exposures—into their models. These factors often modulate the expression of genes involved in drug metabolism, meaning that a patient’s "genomic potential" may be significantly altered by their lived environment.
Official Perspective: Empowering the Next Generation
The decision to make this a "trainee-led" session is intentional. By placing emerging scientists—postdoctoral fellows, PhD candidates, and early-career clinicians—at the center of the conversation, the ASHG is fostering a culture of innovation.
"The next generation of geneticists is not beholden to the traditional silos of the past," says Evelyn Mantegani, media contact for the ASHG. "They are naturally interdisciplinary. They think in terms of data science, bioinformatics, and clinical application simultaneously. This session is designed to give them the stage to demonstrate how they are solving the problems of tomorrow."
Implications for Future Clinical Practice
The findings discussed in this session have profound implications for the future of healthcare. If successfully implemented, these methodologies could lead to:
- Reduced Adverse Drug Reactions: By identifying "at-risk" genotypes and environmental modifiers before a prescription is written, clinicians could prevent millions of annual hospitalizations related to drug toxicity.
- Optimized Dosing: Moving beyond "one-size-fits-all" dosing to personalized regimens based on a patient’s unique multiomic profile.
- Increased Drug Development Success: Pharmaceutical companies are increasingly using these methods to identify potential drug responders during the clinical trial phase, significantly reducing the cost and time required to bring new, effective therapies to market.
- Health Equity: By intentionally including diverse populations in biobank research and clinical algorithms, the medical community can begin to close the health equity gap in pharmacotherapy.
Conclusion: A Forward-Looking Vision
As the American Society of Human Genetics continues to lead the global conversation on genomic science, the focus on multiomics marks a pivotal maturation of the field. The journey from identifying a single gene to understanding the complex, multi-layered biological and environmental symphony that dictates how we respond to medication is long, but the destination is clear: a future where every patient receives the right drug, at the right dose, for the right biological reason.
The research presented at this upcoming session serves as a blueprint for that future. It is a testament to the fact that while genetics may provide the map, it is the integration of multiomics, diversity, and clinical data that will ultimately allow us to navigate the complexities of human health.
About the American Society of Human Genetics (ASHG)
The American Society of Human Genetics (ASHG) is the primary professional membership organization for human genetics specialists worldwide. With a membership of nearly 8,000 professionals, including clinicians, researchers, and educators, the ASHG is dedicated to advancing the understanding of the human genome and its application to health and society. Through its journals, The American Journal of Human Genetics and Human Genetics and Genomics Advances, and its annual meeting, the Society remains at the forefront of genetic discovery and policy advocacy.
For further information, please visit www.ashg.org.
About the Author
